{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:32:10Z","timestamp":1790346730764,"version":"4.1.0"},"reference-count":190,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","award":["C-1970"],"award-info":[{"award-number":["C-1970"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIGMS","doi-asserted-by":"publisher","award":["R35-GM133706"],"award-info":[{"award-number":["R35-GM133706"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["WO2023004348A1"],"award-info":[{"award-number":["WO2023004348A1"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["EP4281116A1"],"award-info":[{"award-number":["EP4281116A1"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["WO2023064802A1"],"award-info":[{"award-number":["WO2023064802A1"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["R21-CA255894"],"award-info":[{"award-number":["R21-CA255894"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["R01-CA277838"],"award-info":[{"award-number":["R01-CA277838"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"DOD","doi-asserted-by":"publisher","award":["W81XWH-22-BCRP-BTA12-2"],"award-info":[{"award-number":["W81XWH-22-BCRP-BTA12-2"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"DOD","doi-asserted-by":"publisher","award":["W81XWH-21-1-0789"],"award-info":[{"award-number":["W81XWH-21-1-0789"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ymthe.2024.03.001","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T03:22:22Z","timestamp":1709695342000},"page":"1219-1237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Engineering small-molecule and protein drugs for targeting bone tumors"],"prefix":"10.1016","volume":"32","author":[{"given":"Yixian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeru","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian Meyer","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang H.-F.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4311-971X","authenticated-orcid":false,"given":"Han","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.03.001_bib1","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx030","article-title":"Annual Report to the Nation on the Status of Cancer, 1975\u20132014, Featuring Survival","volume":"109","author":"Jemal","year":"2017","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.ymthe.2024.03.001_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022. CA","volume":"72","author":"Siegel","year":"2022","journal-title":"Cancer J. Clin."},{"key":"10.1016\/j.ymthe.2024.03.001_bib3","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/jnci\/djt299","article-title":"Secular Trends in Colon and Rectal Cancer Relative Survival","volume":"105","author":"Rutter","year":"2013","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.ymthe.2024.03.001_bib4","doi-asserted-by":"crossref","first-page":"482","DOI":"10.21037\/atm.2020.03.55","article-title":"Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study","volume":"8","author":"Huang","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ymthe.2024.03.001_bib5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ymthe.2024.03.001_bib6","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2024.03.001_bib7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: a fatal attraction","volume":"11","author":"Weilbaecher","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2024.03.001_bib8","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of Bone Metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.03.001_bib9","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/ijc.27402","article-title":"The contrasting age-incidence patterns of bone tumours in teenagers and young adults: Implications for aetiology","volume":"131","author":"Arora","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2024.03.001_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00150","article-title":"Biomarkers of Osteosarcoma, Chondrosarcoma, and Ewing Sarcoma","volume":"8","author":"Evola","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ymthe.2024.03.001_bib11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/BLO.0b013e318059b8c9","article-title":"Osteosarcoma, Chondrosarcoma, and Ewing\u2019s Sarcoma: National Cancer Data Base Report","volume":"459","author":"Damron","year":"2007","journal-title":"Clin. Orthop."},{"key":"10.1016\/j.ymthe.2024.03.001_bib12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13569-020-00144-6","article-title":"Seeking international consensus on approaches to primary tumour treatment in Ewing sarcoma","volume":"10","author":"Gerrand","year":"2020","journal-title":"Clin. Sarcoma Res."},{"key":"10.1016\/j.ymthe.2024.03.001_bib13","doi-asserted-by":"crossref","first-page":"317ra197","DOI":"10.1126\/scitranslmed.aad0295","article-title":"RANKL blockade prevents and treats aggressive osteosarcomas","volume":"7","author":"Chen","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2024.03.001_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016022","article-title":"Survival after bone metastasis by primary cancer type: a Danish population-based cohort study","volume":"7","author":"Svensson","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.ymthe.2024.03.001_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3390\/pharmaceutics10040205","article-title":"Targeted Nanomedicine to Treat Bone Metastasis","volume":"10","author":"Adjei","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ymthe.2024.03.001_bib16","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.1991.9.3.509","article-title":"Bone metastases: pathophysiology and management policy","volume":"9","author":"Nielsen","year":"1991","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.03.001_bib17","doi-asserted-by":"crossref","first-page":"1123S","DOI":"10.3945\/ajcn.2010.28608A","article-title":"Skeletal muscle loss: cachexia, sarcopenia, and inactivity","volume":"91","author":"Evans","year":"2010","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.ymthe.2024.03.001_bib18","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1172\/JCI133572","article-title":"Muscle-derived interleukin 6 increases exercise capacity by signaling in osteoblasts","volume":"130","author":"Chowdhury","year":"2020","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2024.03.001_bib19","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/nm.3961","article-title":"Excess TGF-\u03b2 mediates muscle weakness associated with bone metastases in mice","volume":"21","author":"Waning","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.03.001_bib20","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1126\/science.1146304","article-title":"Dynamic Visualization of Thrombopoiesis Within Bone Marrow","volume":"317","author":"Junt","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2024.03.001_bib21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nri1779","article-title":"Bone-marrow haematopoietic-stem-cell niches","volume":"6","author":"Wilson","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2024.03.001_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/cmi.2011.47","article-title":"Bone marrow and the control of immunity","volume":"9","author":"Zhao","year":"2012","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ymthe.2024.03.001_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.585402","article-title":"The Role of the Bone Marrow Microenvironment in the Response to Infection","volume":"11","author":"Johnson","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.03.001_bib24","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/bjc.1987.13","article-title":"The clinical course of bone metastases from breast cancer","volume":"55","author":"Coleman","year":"1987","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ymthe.2024.03.001_bib25","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/1097-0142(20000715)89:2<363::AID-CNCR22>3.0.CO;2-3","article-title":"Predictors of skeletal complications in patients with metastatic breast carcinoma","volume":"89","author":"Domchek","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ymthe.2024.03.001_bib26","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2024.03.001_bib27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41413-023-00260-1","article-title":"Bone serves as a transfer station for secondary dissemination of breast cancer","volume":"11","author":"Huang","year":"2023","journal-title":"Bone Res."},{"key":"10.1016\/j.ymthe.2024.03.001_bib28","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.breast.2013.10.007","article-title":"Primary and secondary distant metastatic breast cancer: Two sides of the same coin","volume":"23","author":"G\u00fcth","year":"2014","journal-title":"The Breast"},{"key":"10.1016\/j.ymthe.2024.03.001_bib29","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1017\/S1462399408000616","article-title":"Molecular mechanisms and treatment of bone metastasis","volume":"10","author":"Clines","year":"2008","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.ymthe.2024.03.001_bib30","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1158\/1535-7163.MCT-07-0234","article-title":"Molecular Biology of Bone Metastasis","volume":"6","author":"Kingsley","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2024.03.001_bib31","first-page":"570","article-title":"The vicious cycle of bone metastases","volume":"2","author":"Guise","year":"2002","journal-title":"J.\u00a0Musculoskelet. Neuronal Interact."},{"key":"10.1016\/j.ymthe.2024.03.001_bib32","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1172\/JCI3523","article-title":"TGF-\u03b2 signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development","volume":"103","author":"Yin","year":"1999","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2024.03.001_bib33","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2217\/fon.12.76","article-title":"The multifaceted actions of PTHrP in skeletal metastasis","volume":"8","author":"Soki","year":"2012","journal-title":"Future Oncol."},{"key":"10.1016\/j.ymthe.2024.03.001_bib34","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.biocel.2006.11.008","article-title":"RANK ligand","volume":"39","author":"Blair","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ymthe.2024.03.001_bib35","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ctrv.2007.09.002","article-title":"RANK ligand as a therapeutic target for bone metastases and multiple myeloma","volume":"34","author":"Roodman","year":"2008","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ymthe.2024.03.001_bib36","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10555-006-9021-3","article-title":"The RANK\/RANKL\/OPG triad in cancer-induced bone diseases","volume":"25","author":"Dougall","year":"2006","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ymthe.2024.03.001_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00511","article-title":"Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond","volume":"5","author":"Walsh","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.03.001_bib38","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.abb.2008.03.018","article-title":"Functions of RANKL\/RANK\/OPG in bone modeling and remodeling","volume":"473","author":"Boyce","year":"2008","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ymthe.2024.03.001_bib39","first-page":"268","article-title":"The OPG\/RANKL\/RANK system in metabolic bone diseases","volume":"4","author":"Hofbauer","year":"2004","journal-title":"J.\u00a0Musculoskelet. Neuronal Interact."},{"key":"10.1016\/j.ymthe.2024.03.001_bib40","first-page":"261","article-title":"Role of transforming growth factor-beta in bone remodeling","author":"Bonewald","year":"1990","journal-title":"Clin. Orthop."},{"key":"10.1016\/j.ymthe.2024.03.001_bib41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bone.2010.08.004","article-title":"TGF-\u03b2 in cancer and bone: Implications for treatment of bone metastases","volume":"48","author":"Ju\u00e1rez","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.ymthe.2024.03.001_bib42","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2308511120","article-title":"The total mass, number, and distribution of immune cells in the human body","volume":"120","author":"Sender","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ymthe.2024.03.001_bib43","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1002\/jbmr.2735","article-title":"Macrophages: Their Emerging Roles in Bone","volume":"30","author":"Sinder","year":"2015","journal-title":"J.\u00a0Bone Miner. Res."},{"key":"10.1016\/j.ymthe.2024.03.001_bib44","article-title":"Siglec-15\/sialic acid axis as a central glyco-immune checkpoint in breast cancer bone metastasis","volume":"121","author":"Wang","year":"2024","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ymthe.2024.03.001_bib45","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1038\/s41467-023-39769-8","article-title":"The checkpoint inhibitor PD-1H\/VISTA controls osteoclast-mediated multiple myeloma bone disease","volume":"14","author":"Fu","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.03.001_bib46","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.ccell.2021.09.005","article-title":"Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment","volume":"39","author":"Kfoury","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2024.03.001_bib47","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s11999-007-0051-0","article-title":"Predictors of Survival in Patients With Bone Metastasis of Lung Cancer","volume":"466","author":"Sugiura","year":"2008","journal-title":"Clin. Orthop."},{"key":"10.1016\/j.ymthe.2024.03.001_bib48","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10555-018-9763-8","article-title":"From genomics to metabolomics: emerging metastatic biomarkers in osteosarcoma","volume":"37","author":"Dean","year":"2018","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ymthe.2024.03.001_bib49","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s40425-019-0793-8","article-title":"Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer","volume":"7","author":"Landi","year":"2019","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2024.03.001_bib50","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.7150\/thno.26370","article-title":"Comparative biodistribution analysis across four different 89Zr-monoclonal antibody tracers-The first step towards an imaging warehouse","volume":"8","author":"Bensch","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.ymthe.2024.03.001_bib51","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.addr.2012.01.012","article-title":"Targeting polymer therapeutics to bone","volume":"64","author":"Low","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2024.03.001_bib52","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3390\/ijms18071345","article-title":"Development of Bone Targeting Drugs","volume":"18","author":"Stapleton","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.03.001_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/1061186X.2014.950668","article-title":"The critical role of bisphosphonates to target bone cancer metastasis: an overview","volume":"23","author":"Singh","year":"2015","journal-title":"J.\u00a0Drug Target."},{"key":"10.1016\/j.ymthe.2024.03.001_bib54","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jconrel.2021.11.005","article-title":"Targeting bone microenvironments for treatment and early detection of cancer bone metastatic niches","volume":"341","author":"Yang","year":"2022","journal-title":"J.\u00a0Control Release"},{"key":"10.1016\/j.ymthe.2024.03.001_bib55","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1517\/17425247.2011.553218","article-title":"Bone marrow-targeted liposomal carriers","volume":"8","author":"Sou","year":"2011","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ymthe.2024.03.001_bib56","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41579-022-00686-0","article-title":"Skeletal infections: microbial pathogenesis, immunity and clinical management","volume":"20","author":"Masters","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ymthe.2024.03.001_bib57","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2967\/jnumed.119.232603","article-title":"Noninvasive PET Imaging of CDK4\/6 Activation in Breast Cancer","volume":"61","author":"Ramos","year":"2020","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.ymthe.2024.03.001_bib58","doi-asserted-by":"crossref","first-page":"261ra154","DOI":"10.1126\/scitranslmed.3009835","article-title":"Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates","volume":"6","author":"Yu","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2024.03.001_bib59","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-021-00770-1","article-title":"LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation","volume":"17","author":"Ahn","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ymthe.2024.03.001_bib60","doi-asserted-by":"crossref","first-page":"84ra44","DOI":"10.1126\/scitranslmed.3002230","article-title":"Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target","volume":"3","author":"Yu","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2024.03.001_bib61","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: A review of their pharmacokinetic properties","volume":"18","author":"Lin","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.ymthe.2024.03.001_bib62","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2165\/00044011-200525020-00003","article-title":"Pharmacokinetic Considerations in Determining the Terminal Elimination Half-Lives of Bisphosphonates: Clin","volume":"25","author":"Lasseter","year":"2005","journal-title":"Drug Investig."},{"key":"10.1016\/j.ymthe.2024.03.001_bib63","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.3390\/molecules25112602","article-title":"Bisphosphonate-Based Molecules as Potential New Antiparasitic Drugs","volume":"25","author":"Branco Santos","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ymthe.2024.03.001_bib64","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0026-895X(24)12222-5","article-title":"Further Insight into Mechanism of Action of Clodronate: Inhibition of Mitochondrial ADP\/ATP Translocase by a Nonhydrolyzable, Adenine-Containing Metabolite","volume":"61","author":"Lehenkari","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ymthe.2024.03.001_bib65","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1359\/jbmr.1998.13.11.1668","article-title":"Heterocycle-Containing Bisphosphonates Cause Apoptosis and Inhibit Bone Resorption by Preventing Protein Prenylation: Evidence from Structure-Activity Relationships in J774 Macrophages","volume":"13","author":"Luckman","year":"1998","journal-title":"J.\u00a0Bone Miner. Res."},{"key":"10.1016\/j.ymthe.2024.03.001_bib66","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1073\/pnas.0601643103","article-title":"The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs","volume":"103","author":"Kavanagh","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ymthe.2024.03.001_bib67","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1006\/bbrc.1999.0224","article-title":"Nitrogen-Containing Bisphosphonates Inhibit Isopentenyl Pyrophosphate Isomerase\/Farnesyl Pyrophosphate Synthase Activity with Relative Potencies Corresponding to Their Antiresorptive Potenciesin\u00a0Vitroandin\u00a0Vivo","volume":"255","author":"Van Beek","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymthe.2024.03.001_bib68","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3390\/nano10050875","article-title":"Bone Diseases: Current Approach and Future Perspectives in Drug Delivery Systems for Bone Targeted Therapeutics","volume":"10","author":"Chindamo","year":"2020","journal-title":"Nanomaterials"},{"key":"10.1016\/j.ymthe.2024.03.001_bib69","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.urolonc.2007.11.004","article-title":"Osteoclast targeted therapy for prostate cancer: Bisphosphonates and beyond","volume":"26","author":"Smith","year":"2008","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.ymthe.2024.03.001_bib70","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/ijc.24758","article-title":"The bisphosphonate zoledronic acid has antimyeloma activity in\u00a0vivo by inhibition of protein prenylation","volume":"126","author":"Guenther","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2024.03.001_bib71","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1007\/s10495-008-0211-z","article-title":"The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis","volume":"13","author":"Sewing","year":"2008","journal-title":"Apoptosis."},{"key":"10.1016\/j.ymthe.2024.03.001_bib72","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/2159-8290.CD-14-0621","article-title":"Real-Time Intravital Imaging Establishes Tumor-Associated Macrophages as the Extraskeletal Target of Bisphosphonate Action in Cancer","volume":"5","author":"Junankar","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2024.03.001_bib73","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bone.2011.03.774","article-title":"The relationship between the chemistry and biological activity of the bisphosphonates","volume":"49","author":"Ebetino","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.ymthe.2024.03.001_bib74","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1021\/acs.bioconjchem.8b00022","article-title":"Bisphosphonate-Linked TrkB Agonist: Cochlea-Targeted Delivery of a Neurotrophic Agent as a Strategy for the Treatment of Hearing Loss","volume":"29","author":"Kempfle","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ymthe.2024.03.001_bib75","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1359\/jbmr.2003.18.2.222","article-title":"Cathepsin K mRNA and protein expression in prostate cancer progression","volume":"18","author":"Brubaker","year":"2003","journal-title":"J.\u00a0Bone Miner. Res."},{"key":"10.1016\/j.ymthe.2024.03.001_bib76","doi-asserted-by":"crossref","first-page":"9894","DOI":"10.1158\/0008-5472.CAN-06-3940","article-title":"A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden","volume":"67","author":"Le Gall","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2024.03.001_bib77","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0167-4838(95)00190-5","article-title":"Acidic amino acid-rich sequences as binding sites of osteonectin to hydroxyapatite crystals","volume":"1292","author":"Fujisawa","year":"1996","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymthe.2024.03.001_bib78","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3390\/ijms17030428","article-title":"Targeted Delivery Systems for Molecular Therapy in Skeletal Disorders","volume":"17","author":"Dang","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.03.001_bib79","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1054\/bjoc.1999.1012","article-title":"Markers of bone turnover for the management of patients with bone metastases from prostate cancer","volume":"82","author":"Garnero","year":"2000","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ymthe.2024.03.001_bib80","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(07)70147-X","article-title":"Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study","volume":"8","author":"Nilsson","year":"2007","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2024.03.001_bib81","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3109\/10611860108997922","article-title":"Novel Drug Delivery System to Bone Using Acidic Oligopeptide: Pharmacokinetic Characteristics and Pharmacological Potential","volume":"9","author":"Sekido","year":"2001","journal-title":"J.\u00a0Drug Target."},{"key":"10.1016\/j.ymthe.2024.03.001_bib82","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3109\/03008200109014246","article-title":"Binding of Bone Sialoprotein, Osteopontin and Synthetic Polypeptides to Hydroxyapatite","volume":"42","author":"Goldberg","year":"2001","journal-title":"Connect. Tissue Res."},{"key":"10.1016\/j.ymthe.2024.03.001_bib83","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1210\/endo.142.3.8024","article-title":"Selective Delivery of Estradiol to Bone by Aspartic Acid Oligopeptide and Its Effects on Ovariectomized Mice","volume":"142","author":"Yokogawa","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.ymthe.2024.03.001_bib84","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1021\/acsnano.5b07828","article-title":"Osteoblast-Targeting-Peptide Modified Nanoparticle for siRNA\/microRNA Delivery","volume":"10","author":"Sun","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.ymthe.2024.03.001_bib85","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nm.2617","article-title":"A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.03.001_bib86","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1021\/bc7002132","article-title":"Osteotropic Peptide That Differentiates Functional Domains of the Skeleton","volume":"18","author":"Wang","year":"2007","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ymthe.2024.03.001_bib87","doi-asserted-by":"crossref","first-page":"9422","DOI":"10.1016\/j.biomaterials.2010.08.064","article-title":"Phosphorylation-dependent mineral-type specificity for apatite-binding peptide sequences","volume":"31","author":"Addison","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.ymthe.2024.03.001_bib88","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.biomaterials.2008.11.008","article-title":"The adsorption of preferential binding peptides to apatite-based materials","volume":"30","author":"Segvich","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.ymthe.2024.03.001_bib89","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/208787a0","article-title":"Binding of Tetracyclines to Bone","volume":"208","author":"Perrin","year":"1965","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.03.001_bib90","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.bmcl.2008.12.051","article-title":"Bone selective effect of an estradiol conjugate with a novel tetracycline-derived bone-targeting agent","volume":"19","author":"Neale","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ymthe.2024.03.001_bib91","first-page":"5671","article-title":"Tetracycline-grafted PLGA nanoparticles as bone-targeting drug delivery system","volume":"10","author":"Wang","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ymthe.2024.03.001_bib92","first-page":"377","article-title":"Tetracyclines and mineralized tissues: review and perspectives","volume":"48","author":"Skinner","year":"1975","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.ymthe.2024.03.001_bib93","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.addr.2004.12.011","article-title":"Bone-targeting macromolecular therapeutics","volume":"57","author":"Wang","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2024.03.001_bib94","article-title":"Non-antibacterial tetracycline formulations: clinical applications in dentistry and medicine","volume":"4","author":"Gu","year":"2012","journal-title":"J.\u00a0Oral Microbiol."},{"key":"10.1016\/j.ymthe.2024.03.001_bib95","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/cncr.30589","article-title":"Treatment pathway of bone sarcoma in children, adolescents, and young adults: Consensus Bone Sarcoma Treatment Pathway","volume":"123","author":"Reed","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ymthe.2024.03.001_bib96","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/1097-0142(197212)30:6<1627::AID-CNCR2820300631>3.0.CO;2-H","article-title":"Recent advances in the chemotherapy of metastatic osteogenic sarcoma","volume":"30","author":"Jaffe","year":"1972","journal-title":"Cancer"},{"key":"10.1016\/j.ymthe.2024.03.001_bib97","doi-asserted-by":"crossref","first-page":"13481","DOI":"10.1073\/pnas.172501499","article-title":"Interaction of dihydrofolate reductase with methotrexate: Ensemble and single-molecule kinetics","volume":"99","author":"Rajagopalan","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ymthe.2024.03.001_bib98","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/0223-5234(92)90117-J","article-title":"A study of the delivery-targeting concept applied to antineoplasic drugs active on human osteosarcoma. I. Synthesis and biological activity in nude mice carrying human osteosarcoma xenografts of gem-bisphosphonic methotrexate analogues","volume":"27","author":"Sturtz","year":"1992","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ymthe.2024.03.001_bib99","first-page":"105","article-title":"Targeted delivery of antineoplastic agent to bone: biodistribution studies of technetium-99m-labeled gem-bisphosphonate conjugate of methotrexate","volume":"37","author":"Hosain","year":"1996","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.ymthe.2024.03.001_bib100","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/10717544.2017.1422295","article-title":"Bone-targeted methotrexate\u2013alendronate conjugate inhibits osteoclastogenesis in\u00a0vitro and prevents bone loss and inflammation of collagen-induced arthritis in\u00a0vivo","volume":"25","author":"Xie","year":"2018","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ymthe.2024.03.001_bib101","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1021\/ja01495a070","article-title":"POTENTIAL ANTICANCER AGENTS. 1 XL. SYNTHESIS OF THE \u03b2-ANOMER OF 9-(D-ARABINOFURANOSYL)-ADENINE","volume":"82","author":"Lee","year":"1960","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ymthe.2024.03.001_bib102","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1021\/jo01128a007","article-title":"CONTRIBUTIONS TO THE STUDY OF MARINE PRODUCTS. XXXIX. THE NUCLEOSIDES OF SPONGES. III. 1 SPONGOTHYMIDINE AND SPONGOURIDINE 2","volume":"20","author":"Bergmann","year":"1955","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ymthe.2024.03.001_bib103","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-Fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2024.03.001_bib104","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1089\/1084978042484830","article-title":"Preclinical Investigations of Drug and Radionuclide Conjugates of Bisphosphonates for the Treatment of Metastatic Bone Cancer","volume":"19","author":"El-Mabhouh","year":"2004","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.ymthe.2024.03.001_bib105","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.nucmedbio.2006.06.004","article-title":"A 99mTc-labeled gemcitabine bisphosphonate drug conjugate as a probe to assess the potential for targeted chemotherapy of metastatic bone cancer","volume":"33","author":"El-Mabhouh","year":"2006","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ymthe.2024.03.001_bib106","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1007\/s00259-008-0728-y","article-title":"188Re-labelled gemcitabine\/bisphosphonate (Gem\/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases","volume":"35","author":"El-Mabhouh","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.ymthe.2024.03.001_bib107","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3727\/096504011X13021877989874","article-title":"A Conjugate of Gemcitabine With Bisphosphonate (Gem\/BP) Shows Potential as a Targeted Bone-Specific Therapeutic Agent in an Animal Model of Human Breast Cancer Bone Metastases","volume":"19","author":"El-Mabhouh","year":"2011","journal-title":"Oncol. Res."},{"key":"10.1016\/j.ymthe.2024.03.001_bib108","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1021\/jo800317e","article-title":"Bisphosphonate Derivatives of Nucleoside Antimetabolites: Hydrolytic Stability and Hydroxyapatite Adsorption of 5\u2032-\u03b2,\u03b3-Methylene and 5\u2032-\u03b2,\u03b3-(1-Hydroxyethylidene) Triphosphates of 5-Fluorouridine and ara -Cytidine","volume":"73","author":"Ora","year":"2008","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ymthe.2024.03.001_bib109","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bone.2010.03.006","article-title":"A promising approach for treatment of tumor-induced bone diseases: Utilizing bisphosphonate derivatives of nucleoside antimetabolites","volume":"47","author":"Reinholz","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.ymthe.2024.03.001_bib110","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.18632\/oncotarget.27801","article-title":"Phase I dose escalation study of 12b80 (hydroxybisphosphonate linked doxorubicin) in naturally occurring osteosarcoma","volume":"11","author":"Boy\u00e9","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2024.03.001_bib111","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1634\/theoncologist.2018-0707","article-title":"First-in-Human Phase I Study of MBC-11, a Novel Bone-Targeted Cytarabine-Etidronate Conjugate in Patients with Cancer-Induced Bone Disease","volume":"24","author":"Zinnen","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ymthe.2024.03.001_bib112","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ygyno.2017.02.019","article-title":"Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation","volume":"145","author":"Ricci","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ymthe.2024.03.001_bib113","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12885-016-2312-3","article-title":"Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone","volume":"16","author":"Palmerini","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ymthe.2024.03.001_bib114","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1021\/acs.bioconjchem.1c00507","article-title":"Gemcitabine\u2013Ibandronate Conjugate Enables the Bone-Targeted Combination Therapy in Bone Cancer: Synthesis and Efficacy in Combination with Docetaxel","volume":"32","author":"Farrell","year":"2021","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ymthe.2024.03.001_bib115","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1016\/j.bmc.2011.04.015","article-title":"N4-[Alkyl-(hydroxyphosphono)phosphonate]-cytidine\u2014New drugs covalently linking antimetabolites (5-FdU, araU or AZT) with bone-targeting bisphosphonates (alendronate or pamidronate)","volume":"19","author":"Schott","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ymthe.2024.03.001_bib116","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1007\/s10637-011-9688-3","article-title":"Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay","volume":"30","author":"Schott","year":"2012","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ymthe.2024.03.001_bib117","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.bone.2006.01.141","article-title":"Bisphosphonate actions: Physical chemistry revisited","volume":"38","author":"Papapoulos","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.ymthe.2024.03.001_bib118","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1021\/ja00968a057","article-title":"Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata 1,2","volume":"88","author":"Wall","year":"1966","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ymthe.2024.03.001_bib119","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1634\/theoncologist.6-6-506","article-title":"The Development of Camptothecin Analogs in Childhood Cancers","volume":"6","author":"Bomgaars","year":"2001","journal-title":"Oncologist"},{"key":"10.1016\/j.ymthe.2024.03.001_bib120","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.bmcl.2007.11.029","article-title":"Chemotherapeutic bone-targeted bisphosphonate prodrugs with hydrolytic mode of activation","volume":"18","author":"Erez","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ymthe.2024.03.001_bib121","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.chembiol.2010.04.012","article-title":"DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs","volume":"17","author":"Pommier","year":"2010","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ymthe.2024.03.001_bib122","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1021\/jm300493m","article-title":"Development of Novel Bisphosphonate Prodrugs of Doxorubicin for Targeting Bone Metastases That Are Cleaved pH Dependently or by Cathepsin B: Synthesis, Cleavage Properties, and Binding Properties to Hydroxyapatite As Well As Bone Matrix","volume":"55","author":"Hochd\u00f6rffer","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ymthe.2024.03.001_bib123","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1593\/neo.04349","article-title":"Bone Microenvironment Modulates Expression and Activity of Cathepsin B in Prostate Cancer","volume":"7","author":"Podgorski","year":"2005","journal-title":"Neoplasia"},{"key":"10.1016\/j.ymthe.2024.03.001_bib124","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1517\/14728222.2013.740461","article-title":"Cathepsin B as a cancer target","volume":"17","author":"Gondi","year":"2013","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ymthe.2024.03.001_bib125","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/0014-4827(88)90191-7","article-title":"Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts\u22171","volume":"175","author":"Silver","year":"1988","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ymthe.2024.03.001_bib126","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1021\/acs.bioconjchem.9b00210","article-title":"12b80\u00a0\u2013 Hydroxybisphosphonate Linked Doxorubicin: Bone Targeted Strategy for Treatment of Osteosarcoma","volume":"30","author":"David","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ymthe.2024.03.001_bib127","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40268-019-0269-9","article-title":"Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later","volume":"19","author":"Robak","year":"2019","journal-title":"Drugs RD"},{"key":"10.1016\/j.ymthe.2024.03.001_bib128","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/1535-7163.MCT-11-0433","article-title":"Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma","volume":"10","author":"Hideshima","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2024.03.001_bib129","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/sj.leu.2404528","article-title":"Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma","volume":"21","author":"Bonvini","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2024.03.001_bib130","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.03.001_bib131","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3324\/haematol.2009.012674","article-title":"Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations","volume":"95","author":"Mohty","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.ymthe.2024.03.001_bib132","doi-asserted-by":"crossref","first-page":"6455","DOI":"10.1016\/j.bmcl.2013.09.043","article-title":"Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma","volume":"23","author":"Agyin","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ymthe.2024.03.001_bib133","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3390\/pharmaceutics10030154","article-title":"Synthesis of a Bone-Targeted Bortezomib with In\u00a0Vivo Anti-Myeloma Effects in Mice","volume":"10","author":"Wang","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ymthe.2024.03.001_bib134","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.drup.2014.12.001","article-title":"Molecular basis of resistance to proteasome inhibitors in hematological malignancies","volume":"18","author":"Niewerth","year":"2015","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.ymthe.2024.03.001_bib135","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1042\/BST20140126","article-title":"Overcoming bortezomib resistance in multiple myeloma","volume":"42","author":"Murray","year":"2014","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.ymthe.2024.03.001_bib136","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/jbmr.4496","article-title":"Bone-Targeted Bortezomib Inhibits Bortezomib-Resistant Multiple Myeloma in Mice by Providing Higher Levels of Bortezomib in Bone","volume":"37","author":"Tao","year":"2022","journal-title":"J.\u00a0Bone Miner. Res."},{"key":"10.1016\/j.ymthe.2024.03.001_bib137","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1038\/sj.onc.1207374","article-title":"The spindle checkpoint, aneuploidy, and cancer","volume":"23","author":"Bharadwaj","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.ymthe.2024.03.001_bib138","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1083\/jcb.200805072","article-title":"Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied","volume":"182","author":"Brito","year":"2008","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.ymthe.2024.03.001_bib139","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1021\/bc500614b","article-title":"Novel Pullulan Bioconjugate for Selective Breast Cancer Bone Metastases Treatment","volume":"26","author":"Bonzi","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ymthe.2024.03.001_bib140","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1016\/j.biomaterials.2013.01.049","article-title":"A nano-hydroxyapatite\u00a0\u2013 Pullulan\/dextran polysaccharide composite macroporous material for bone tissue engineering","volume":"34","author":"Fricain","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.ymthe.2024.03.001_bib141","first-page":"1000164","article-title":"Paclitaxel Nano-Delivery Systems: A Comprehensive Review","volume":"4","author":"Ma","year":"2013","journal-title":"J.\u00a0Nanomed. Nanotechnol."},{"key":"10.1016\/j.ymthe.2024.03.001_bib142","doi-asserted-by":"crossref","first-page":"12517","DOI":"10.1074\/jbc.271.21.12517","article-title":"Proteolytic Activity of Human Osteoclast Cathepsin K","volume":"271","author":"Bossard","year":"1996","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2024.03.001_bib143","doi-asserted-by":"crossref","first-page":"12511","DOI":"10.1074\/jbc.271.21.12511","article-title":"Cathepsin K, but Not Cathepsins B, L, or S, Is Abundantly Expressed in Human Osteoclasts","volume":"271","author":"Drake","year":"1996","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2024.03.001_bib144","doi-asserted-by":"crossref","first-page":"7606","DOI":"10.1073\/pnas.93.15.7606","article-title":"Influence of cisplatin intrastrand crosslinking on the conformation, thermal stability, and energetics of a 20-mer DNA duplex","volume":"93","author":"Poklar","year":"1996","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ymthe.2024.03.001_bib145","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/BF00689452","article-title":"Persistence of cisplatin-induced DNA interstrand crosslinking in peripheral blood mononuclear cells from elderly and young individuals","volume":"35","author":"Rudd","year":"1995","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ymthe.2024.03.001_bib146","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/BF01612916","article-title":"Anticancer-agent-linked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bone-related malignancies?","volume":"116","author":"Klenner","year":"1990","journal-title":"J.\u00a0Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.03.001_bib147","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1248\/cpb.59.710","article-title":"Dialkyl Bisphosphonate Platinum(II) Complex as a Potential Drug for Metastatic Bone Tumor","volume":"59","author":"Nakatake","year":"2011","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.ymthe.2024.03.001_bib148","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nucmedbio.2018.05.003","article-title":"The impact of age on radium-223 distribution and an evaluation of molecular imaging surrogates","volume":"62\u201363","author":"Jiang","year":"2018","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ymthe.2024.03.001_bib149","doi-asserted-by":"crossref","first-page":"6250s","DOI":"10.1158\/1078-0432.CCR-06-0841","article-title":"High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the \u03b1-Emitter 223Ra:\u00a0Adjuvant or Alternative to Conventional Modalities?","volume":"12","author":"Bruland","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2024.03.001_bib150","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.03.001_bib151","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3390\/medicina55050149","article-title":"Retrospective Toxicological Profiling of Radium-223 Dichloride for the Treatment of Bone Metastases in Prostate Cancer Using Adverse Event Data","volume":"55","author":"Soldatos","year":"2019","journal-title":"Medicina (Mex.)"},{"key":"10.1016\/j.ymthe.2024.03.001_bib152","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s12663-019-01211-2","article-title":"Bisphosphonate-Induced Osteonecrosis of the Jaws (BIONJ)","volume":"19","author":"Singh","year":"2020","journal-title":"J.\u00a0Maxillofac. Oral Surg."},{"key":"10.1016\/j.ymthe.2024.03.001_bib153","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ymthe.2024.03.001_bib154","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.bone.2007.04.196","article-title":"Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?","volume":"41","author":"Reid","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.ymthe.2024.03.001_bib155","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.bone.2008.01.003","article-title":"Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis","volume":"42","author":"Rizzoli","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.ymthe.2024.03.001_bib156","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ejca.2012.07.016","article-title":"Denosumab for treatment of bone metastases secondary to solid tumours: Systematic review and network meta-analysis","volume":"49","author":"Ford","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ymthe.2024.03.001_bib157","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/1758834011412656","article-title":"Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion","volume":"3","author":"Steger","year":"2011","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.ymthe.2024.03.001_bib158","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"The Lancet"},{"key":"10.1016\/j.ymthe.2024.03.001_bib159","doi-asserted-by":"crossref","first-page":"45826","DOI":"10.1074\/jbc.M309024200","article-title":"Angiostatin Inhibits Bone Metastasis Formation in Nude Mice through a Direct Anti-osteoclastic Activity","volume":"278","author":"Peyruchaud","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2024.03.001_bib160","first-page":"4432","article-title":"Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis","volume":"61","author":"Morony","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2024.03.001_bib161","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/cncr.11138","article-title":"A Phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases","volume":"97","author":"Body","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ymthe.2024.03.001_bib162","first-page":"4040","article-title":"An experimental model of bone metastasis by human lung cancer cells: the role of parathyroid hormone-related protein in bone metastasis","volume":"56","author":"Iguchi","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2024.03.001_bib163","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1172\/JCI118947","article-title":"Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis","volume":"98","author":"Guise","year":"1996","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2024.03.001_bib164","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/annonc\/mds221","article-title":"Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer","volume":"23","author":"Gullo","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ymthe.2024.03.001_bib165","series-title":"Atezolizumab (TECENTRIQ)","year":"2018"},{"key":"10.1016\/j.ymthe.2024.03.001_bib166","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.03.001_bib167","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41413-023-00246-z","article-title":"Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment","volume":"11","author":"Tian","year":"2023","journal-title":"Bone Res."},{"key":"10.1016\/j.ymthe.2024.03.001_bib168","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf2051","article-title":"Harnessing the power of antibodies to fight bone metastasis","volume":"7","author":"Tian","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2024.03.001_bib169","article-title":"Bone-Specific Enhancement of Antibody Therapy for Breast Cancer Metastasis to Bone","author":"Tian","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.ymthe.2024.03.001_bib170","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1021\/acs.bioconjchem.8b00680","article-title":"Proximity-Induced Site-Specific Antibody Conjugation","volume":"29","author":"Yu","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ymthe.2024.03.001_bib171","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1021\/acs.bioconjchem.1c00342","article-title":"Precision Modification of Native Antibodies","volume":"32","author":"Wu","year":"2021","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ymthe.2024.03.001_bib172","article-title":"Advancing protein therapeutics through proximity-induced chemistry","author":"Cheng","year":"2023","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ymthe.2024.03.001_bib173","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0169-409X(95)00041-5","article-title":"Exploiting bone marrow microvascular structure for drug delivery and future therapies","volume":"17","author":"Moghimi","year":"1995","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2024.03.001_bib174","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2165\/00003088-200342150-00002","article-title":"Bone-Specific Drug Delivery Systems: Approaches via Chemical Modification of Bone-Seeking Agents","volume":"42","author":"Hirabayashi","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ymthe.2024.03.001_bib175","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1021\/mp8002368","article-title":"Improved Bone Delivery of Osteoprotegerin by Bisphosphonate Conjugation in a Rat Model of Osteoarthritis","volume":"6","author":"Doschak","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ymthe.2024.03.001_bib176","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ijpharm.2010.04.015","article-title":"Synthesis, characterization and in\u00a0vitro evaluation of a bone targeting delivery system for salmon Calcitonin","volume":"394","author":"Bhandari","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ymthe.2024.03.001_bib177","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/jps.22773","article-title":"Development of Bone-Targeted Catalase Derivatives for Inhibition of Bone Metastasis of Tumor Cells in Mice","volume":"101","author":"Zheng","year":"2012","journal-title":"J.\u00a0Pharm. Sci."},{"key":"10.1016\/j.ymthe.2024.03.001_bib178","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1016\/j.biomaterials.2013.01.059","article-title":"Bifunctional bisphosphonates for delivering PTH (1-34) to bone mineral with enhanced bioactivity","volume":"34","author":"Yewle","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.ymthe.2024.03.001_bib179","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.2147\/DDDT.S154922","article-title":"Profile of asfotase alfa in the treatment of hypophosphatasia: design, development, and place in therapy","volume":"12","author":"Bowden","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ymthe.2024.03.001_bib180","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.canlet.2008.02.031","article-title":"Reactive oxygen species in tumor metastasis","volume":"266","author":"Nishikawa","year":"2008","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ymthe.2024.03.001_bib181","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.addr.2009.01.001","article-title":"Catalase delivery for inhibiting ROS-mediated tissue injury and tumor metastasis","volume":"61","author":"Nishikawa","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2024.03.001_bib182","first-page":"333","article-title":"Targeted and intracellular delivery of protein therapeutics by a boronated polymer for the treatment of bone tumors","volume":"7","author":"Yan","year":"2022","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.ymthe.2024.03.001_bib183","doi-asserted-by":"crossref","first-page":"5963","DOI":"10.3390\/curroncol29080471","article-title":"Cathepsin K: A Versatile Potential Biomarker and Therapeutic Target for Various Cancers","volume":"29","author":"Qian","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ymthe.2024.03.001_bib184","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.stem.2023.04.005","article-title":"Osteoprogenitor-GMP crosstalk underpins solid tumor-induced systemic immunosuppression and persists after tumor removal","volume":"30","author":"Hao","year":"2023","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2024.03.001_bib185","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bone.2007.09.044","article-title":"Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts","volume":"42","author":"Fuller","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.ymthe.2024.03.001_bib186","doi-asserted-by":"crossref","first-page":"13453","DOI":"10.1073\/pnas.95.23.13453","article-title":"Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice","volume":"95","author":"Saftig","year":"1998","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ymthe.2024.03.001_bib187","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3109\/03602531003745960","article-title":"Qualitative structure-metabolism relationships in the hydrolysis of carbamates","volume":"42","author":"Vacondio","year":"2010","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.ymthe.2024.03.001_bib188","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3109\/14756368809040726","article-title":"Structure and Dynamics of Serine Hydrolase-Organophosphate Adducts","volume":"2","author":"Kovach","year":"1988","journal-title":"J.\u00a0Enzyme Inhib."},{"key":"10.1016\/j.ymthe.2024.03.001_bib189","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.apsb.2018.05.005","article-title":"Human carboxylesterases: a comprehensive review","volume":"8","author":"Wang","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ymthe.2024.03.001_bib190","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1021\/tx060117m","article-title":"Serine Hydrolase KIAA1363: Toxicological and Structural Features with Emphasis on Organophosphate Interactions","volume":"19","author":"Nomura","year":"2006","journal-title":"Chem. Res. Toxicol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624001424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624001424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T09:20:27Z","timestamp":1746091227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624001424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":190,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1525001624001424"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.03.001","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering small-molecule and protein drugs for targeting bone tumors","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}